Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENX-104 in major depressive disorder with anhedonia
NCT07253324Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in major depressive disorder (MDD) comparing ENX-104 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 21 days. Started Feb 2025; status: completed.
02
Drugs
ENX-104
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07253324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253324.